Home・Elenco Azioni・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Chiusa

SettoreSettore sanitario

35.58 0.71

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.65

Massimo

35.79

Metriche Chiave
By Trading Economics
Entrata	-2.5M 14M
Vendite	-12M 194M
P/E Media del settore	17.077 64.641
EPS	1.76
Margine di Profitto	7.491
Dipendenti	423
EBITDA	-213M 91M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+61.13% upside

Dividendi
By Acuity
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	31M 1.2B
Apertura precedente	34.87
Chiusura precedente	35.58

Notizie sul Sentiment di mercato

By Acuity

34%

66%

104 / 340 Classifica in Healthcare

Collegium Pharmaceutical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 ago 2026, 19:46 UTC

Collegium Pharmaceutical Inc is trading lower today, continuing a three-session decline. The stock peaked early but has since pulled back.

31 lug 2026, 20:06 UTC

News

Collegium Pharmaceutical is under scrutiny due to concerns over its financial performance, contributing to a decline in shares during Friday's session.

30 lug 2026, 20:09 UTC

Collegium Pharmaceutical Inc shares are lower in Thursday's session, with no specific news to explain the decline amid broader market volatility.

29 lug 2026, 22:01 UTC

Collegium Pharmaceutical Inc is trading higher in after-market hours, continuing a positive trend with gains over four consecutive sessions amid cautious investor sentiment.

28 lug 2026, 22:01 UTC

Collegium Pharmaceutical Inc shares are lower in after-market hours, continuing a decline from Tuesday's close amid broader market pressures, particularly in Asia.

27 lug 2026, 19:07 UTC

News

Collegium Pharmaceutical reported first-quarter revenues of $193.5 million, surpassing expectations, while shares are trading higher amid broader strength in the pharmaceutical sector.

24 lug 2026, 19:46 UTC

Collegium Pharmaceutical Inc shares are lower during Friday's session, with no specific news identified to explain the decline. The stock remains near its one-month trading range.

22 lug 2026, 20:01 UTC

Collegium Pharmaceutical Inc shares are lower today, continuing a downward trend seen since Tuesday's close, with no specific news identified for the decline.

21 lug 2026, 20:01 UTC

Collegium Pharmaceutical Inc is trading higher amid a broader market rally, with the Pharmaceuticals sector also gaining momentum. No specific news was identified.

20 lug 2026, 19:41 UTC

News

Collegium Pharmaceutical plans to move its headquarters to Boston in 2027. Shares are lower amid significant declines in the Pharmaceuticals sub-sector.

Confronto tra pari

Modifica del prezzo

Collegium Pharmaceutical Inc Previsione

Obiettivo di Prezzo

By TipRanks

61.13% in crescita

Previsioni per 12 mesi

Media 57.33 USD 61.13%

Alto 60 USD

Basso 56 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Collegium Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Collegium Pharmaceutical Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

104 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.